21 completed, 10 recruiting, 7 not yet recruiting, 5 active not recruiting. 12 Phase 2, 9 Phase 4, 7 Phase 1, 3 Not applicable, 3 Phase 3.
Follow vericiguat: new trials by email Literature Review of vericiguat trials Research Report on vericiguat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway Vericiguat 10 MG, Placebo, Insulin Sensitivity Test - Cardiovascular Diseases, Insulin Sensitivity/Resistance | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 200 | 2026-12-01 | 2026-01-23 |
| Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression Vericiguat (BAY1021189), Placebo - Calcific Aortic Valve Disease, AORTIC VALVE DISEASES | Phase 2 | Recruiting | West China Hospital | 238 | 2026-09-24 | 2026-09-25 |
| Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients Vericiguat tablet, Placebo - Heart Failure With Reduced Ejection Fraction (HFrEF) | Phase 4 | Not yet recruiting | National Institute of Cardiovascular Diseases, Pakistan | 500 | 2026-07-15 | 2026-07-13 |
| Efficacy of Verciguat in TR and RV Failure Vericiguat - HFrEF, Tricuspid Regurgitation (TR) | Phase 4 | Not yet recruiting | Daejeon St. Mary's hospital | 100 | 2026-07-01 | 2026-06-25 |
| Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery Vericiguat, Standard of Care Group - Cardio Vascular Disease, Cardiopulmonary Bypass | Not applicable | Not yet recruiting | Nanjing Medical University | 600 | 2026-05-31 | 2026-05-18 |
| Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial Vericiguat tablet, Sacubitril / Valsartan - Decompensated Heart Failure | Phase 1 | Recruiting | Khawaja Danish Ali | 130 | 2026-01-01 | 2026-03-02 |
| Vericiguat and Reverse Remodeling Indices in Heart Failure Vericiguat, Guideline Directed Medical Therapy for Heart Failure (GDMT) - Heart Failure With Reduced Ejection Fraction (HFrEF), Chronic Heart Failure | Phase 4 | Recruiting | University Medical Centre Ljubljana | 70 | 2025-11-01 | 2026-09-29 |
| An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions Vericiguat (Verquvo, BAY1021189) - Chronic Heart Failure With Reduced Ejection Fraction, Worsening Chronic Heart Failure | Active not recruiting | Bayer | 604 | 2025-09-08 | 2026-06-02 | |
| COgnitioN With VERiciGuat Evaluation in Heart Failure Vericiguat - Heart Failure, Cognitive Impairment | Phase 2 | Recruiting | University of Alberta | 120 | 2025-06-03 | 2026-08-25 |
| A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure Vericiguat - Hemodialysis Complication, Heart Failure | Not applicable | Recruiting | Guangdong Provincial People's Hospital | 118 | 2025-06-01 | 2025-07-09 |
| Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction Vericiguat - Heart Failure, Acute Myocardial Infarction (AMI) | Phase 4 | Not yet recruiting | Dongying Zhang | 200 | 2025-04-01 | 2025-02-06 |
| The Impact of Vericiguat on Microvascular Function in Patients With Documented Vasospastic Angina Pectoris Vericiguat - Vasospastic Angina | Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 57 | 2025-02-10 | 2026-07-29 |
| Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction Vericiguat Oral Tablet [Verquvo], Prescription Drugs - HFrEF - Heart Failure With Reduced Ejection Fraction, Myocardial Infarction (MI) | Not yet recruiting | Qilu Hospital of Shandong University | 210 | 2025-01-01 | 2024-12-04 | |
| The CardioMEMS Vericiguat Heart Failure Trial Vericiguat, Placebo - Heart Failure, Pulmonary Arterial Hypertension | Phase 4 | Not yet recruiting | Finn Gustafsson | 17 | 2024-12-01 | 2024-11-04 |
| An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan vericiguat (BAY 1021189) - Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction | Completed | Bayer | 4936 | 2024-11-01 | 2025-10-08 | |
| Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM) Vericiguat, Stress Cardiac Magnetic Resonance - Chest Pain | Not applicable | Recruiting | The University of Hong Kong | 94 | 2024-09-01 | 2026-06-29 |
| An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany Vericiguat (Verquvo, BAY1021189) - Chronic Heart Failure With Reduced Ejection Fraction | Completed | Bayer | 500 | 2024-07-05 | 2026-08-31 | |
| A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction Vericiguat (BAY1021189) 5 mg - Chronic Heart Failure With Reduced Ejection Fraction | Phase 2 | Completed | Bayer | 106 | 2024-04-18 | 2025-09-25 |
| An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States Vericiguat (Verquvo, BAY1021189) - Chronic Heart Failure With Reduced Ejection Fraction | Completed | Bayer | 1400 | 2024-04-10 | 2024-07-03 | |
| Vericiguat and Exercise Hemodynamics in Patients With HFrEF Vericiguat, Guideline-directed medical therapy (GDMT) for heart failure - Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure | Completed | Argyrios Ntalianis | 40 | 2024-01-31 | 2026-07-13 |
Showing 20 of 43. Sign in to see all of them.
Heart Failure (16) · Coronary Artery Disease (3) · Cardiovascular Diseases (2) · Insulin Resistance (2) · Angina Pectoris, Variant (1) · Aortic Valve Disease (1) · Aortic Valve Stenosis (1) · Brain Diseases (1) · Breast Neoplasms (1) · Chest Pain (1) · Cognitive Dysfunction (1) · Emergencies (1) · Fatigue Syndrome, Chronic (1) · Fibrosis (1) · Inflammation (1)
Bayer (18) · Merck Sharp & Dohme LLC (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Argyrios Ntalianis (1) · Beijing Tsinghua Chang Gung Hospital (1) · Charite University, Berlin, Germany (1) · Daejeon St. Mary's hospital (1) · Dongying Zhang (1) · Finn Gustafsson (1) · Guangdong Provincial People's Hospital (1) · Johns Hopkins University (1) · Josef Stehlik (1) · Khawaja Danish Ali (1) · Memorial Sloan Kettering Cancer Center (1) · Nanjing Medical University (1)
Germany (13) · United States (13) · China (8) · Canada (6) · Hungary (6) · Italy (6) · Poland (6) · South Korea (6) · Spain (6) · Greece (5) · Japan (5) · Netherlands (5) · Singapore (5) · Sweden (5) · Austria (4)
Anthony Yu, MD, MS (1) · Argyrios Ntalianis, MD, PhD (1) · Burkert Pieske, MD (1) · Christopher M. O'Connor, MD (1) · Dongying Zhang, Professor (1) · Finn Gustafsson, Professor (1) · Ghazala Irfan, FCPS (1) · Gregor Poglajen, MD, PhD (1) · Josef Stehlik, M.D, M.P.H. (1) · Judith Bellmann-Strobl, MD (1) · Justin Ezekowitz, MBBCh, MSc (1) · Mahesh J. Patel, MD (1) · Marcos Lopez, MD (1)
PMID 32222134, PMID 14744970, PMID 22357361, PMID 24621874, PMID 25056511, PMID 26547357, PMID 29032136, PMID 29496021, PMID 31535829, PMID 31820546, PMID 32216011, PMID 33039447, PMID 33079152, PMID 33185650, PMID 34086190, PMID 34216757, PMID 34407626, PMID 34432985, PMID 34449189, PMID 34743540, PMID 35299288, PMID 35656822, PMID 35791083, PMID 35880474, PMID 36049817, PMID 36250238, PMID 36633816, PMID 36881394, PMID 37137660, PMID 37191077, PMID 37208936, PMID 37331690, PMID 37417824, PMID 37503602, PMID 37565973, PMID 37671551, PMID 37672197, PMID 38363272, PMID 38916717, PMID 38934967, PMID 39134125, PMID 39206547, PMID 39473305, PMID 40897189, PMID 41058565, PMID 42034271, PMID 42670734
2016 (2), 2014 (1), 2015 (1), 2017 (1), 2018 (1), 2023 (1), R01HL164909 (1)